Eli Lilly 2015 Annual Report Download - page 103

Download and view the complete annual report

Please find page 103 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 186

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186

F91
FINANCIAL REPORT
Our human pharmaceutical products segment includes the discovery, development, manufacturing,
marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas:
endocrinology, neuroscience, oncology, cardiovascular, and other. We lost U.S. patent exclusivity for
Cymbalta in December 2013 and Evista® in March 2014, which resulted in the immediate entry of generic
competitors and a rapid and severe decline in revenue.
Our animal health segment, operating through our Elanco animal health division, includes the development,
manufacturing, marketing, and sales of animal health products worldwide for both food and companion
animals. Animal health products include Rumensin®, Posilac®, Tylan®, Denagard®, Maxiban®, Optaflexx®, and
other products for livestock and poultry, as well as Trifexis®, Comfortis®, and other products for companion
animals. The animal health segment amounts for the year ended December 31, 2015 include the results of
operations from Novartis AH, which was acquired on January 1, 2015 (Note 3).
Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians
and other health care professionals, and hospitals. For the years ended December 31, 2015, 2014, and 2013,
our three largest wholesalers each accounted for between 8 percent and 19 percent of consolidated total
revenue. Further, they each accounted for between 9 percent and 16 percent of accounts receivable as of
December 31, 2015 and 2014. Animal health products are sold primarily to wholesale distributors.
We manage our assets on a total company basis, not by operating segment, as the assets of the animal
health business are intermixed with those of the pharmaceutical products business. Therefore, our chief
operating decision maker does not review any asset information by operating segment and, accordingly, we
do not report asset information by operating segment.
We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign
operations, and our results of operations and the value of our foreign assets are affected by fluctuations in
foreign currency exchange rates.
The following table summarizes our revenue activity:
2015 2014 2013
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology:
Humalog®$ 2,841.9 $ 2,785.2 $ 2,611.2
Forteo®1,348.3 1,322.0 1,244.9
Humulin®1,307.4 1,400.1 1,315.8
Trajenta 356.8 328.8 249.2
Trulicity®248.7 10.2 —
Evista 237.3 419.8 1,050.4
Other Endocrinology 696.4 672.9 832.9
Total Endocrinology 7,036.8 6,939.0 7,304.4
Neuroscience:
Cymbalta 1,027.6 1,614.7 5,084.4
Zyprexa®940.3 1,037.3 1,194.8
Strattera®784.0 738.5 709.2
Other Neuroscience 183.5 206.0 227.8
Total Neuroscience 2,935.4 3,596.5 7,216.2